نتائج البحث - "Matthias Zeis"

المساهمون: Takeda Pharmaceutical Company, Dimopoulos MA1, Gay F2, Schjesvold F3, Beksac M4, Hajek R5, Weisel KC6, Goldschmidt H7, Maisnar V8, Moreau P9, Min CK10, Pluta A11, Chng WJ12, Kaiser M13, Zweegman S14, Mateos MV15, Spencer A16, Iida S17, Morgan G18, Suryanarayan K19, Teng Z19, Skacel T19, Palumbo A20, Dash AB19, Gupta N19, Labotka R19, Rajkumar SV21, TOURMALINE-MM3 study group. Bar D, Basso A, Fantl D, He S, Horvath N, Lee C, Rowlings P, Taylor K, Spencer A, Cochrane T, Kwok F, Ramanathan S, Agis H, Zojer N, Kentos A, Offner F, Van Droogenbroeck J, Wu KL, Maiolino A, Martinez G, Zanella K, Capra M, Araújo S, Gregora E, Hajek R, Maisnar V, Pour L, Scudla V, Spicka I, Abildgaard N, Andersen N, Jensen BA, Helleberg C, Plesner T, Salomo M, Svirskaite A, Delarue R, Moreau P, Blau I, Goldschmidt H, Schieferdecker A, Teleanu V, Munder M, Röllig C, Salwender HJ, Fuhrmann S, Weisel K, Duerig J, Zeis M, Klein S, Reimer P, Schmidt C, Scheid C, Mayer K, Hoffmann M, Sosada M, Dimopoulos A, Delimpasi S, Kyrtsonis MC, Anagnostopoulos A, Nagy Z, Illés Á, Egyed M, Borbényi Z, Mikala G, Dally N, Horowitz N, Gutwein O, Nemets A, Vaxman I, Shvetz O, Trestman S, Ruchlemer R, Nagler A, Tadmor T, Rouvio O, Preis M, Gay F, Cavo M, De Rosa L, Musto P, Cafro A, Tosi P, Offidani M, Corso A, Rossi G, Liberati AM, Bosi A, Suzuki K, Iida S, Nakaseko C, Ishikawa T, Matsumoto M, Nagai H, Sunami K, Chou T, Akashi K, Takezako N, Hagiwara S, Eom HS, Jo DY, Kim JS, Lee JH, Min CK, Yoon SS, Yoon DH, Kim K, Zweegman S, Levin MD, Vellenga E, Minnema M, Schjesvold F, Waage A, Haukås E, Grosicki S, Pluta A, Robak T, Marques H, Bergantim R, Campilho F, Chng WJ, Goh YT, McDonald A, Rapoport B, Álvarez Rivas MA, De Arriba de La Fuente F, González Montes Y, Martin Sanchez J, Mateos MV, Oriol Rocafiguera A, Rosinol L, San Miguel J, Pérez de Oteyza J, Encinas C, Alegre-Amor A, López-Guía A, Axelsson P, Carlson K, Stromberg O, Hansson M, Hveding Blimark C, Mueller R, Chen CC, Liu TC, Huang SY, Wang PN, Na Nakorn T, Prayongratana K, Beksac M, Unal A, Goker H, Sonmez M, Korenkova S, Chaidos A, Oakervee H, Sati H, Benjamin R, Wechalekar A, Garg M, Kaiser M, Ramasamy K, Cook G, Chantry A, Jenner M, Buadi F, Berryman R, Janakiram M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, Hematology

المصدر: Dimopoulos, M A, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, K C, Goldschmidt, H, Maisnar, V, Moreau, P, Min, C K, Pluta, A, Chng, W-J, Kaiser, M, Zweegman, S, Mateos, M-V, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, Z, Skacel, T, Palumbo, A, Dash, A B, Gupta, N, Labotka, R, Rajkumar, S V, Abildgaard, N & TOURMALINE-MM3 study group 2019, ' Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 253-264 . https://doi.org/10.1016/S0140-6736Test(18)33003-4
Dimopoulos, M A, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, K C, Goldschmidt, H, Maisnar, V, Moreau, P, Min, C K, Pluta, A, Chng, W J, Kaiser, M, Zweegman, S, Mateos, M V, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, Z, Skacel, T, Palumbo, A, Dash, A B, Gupta, N, Labotka, R, Rajkumar, S V, Kwok, F & TOURMALINE-MM3 study group 2019, ' Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial ', The Lancet, vol. 393, no. 10168, pp. 253-264 . https://doi.org/10.1016/S0140-6736Test(18)33003-4
Digital.CSIC. Repositorio Institucional del CSIC
instname
Lancet, 393(10168), 253. Elsevier Limited
LANCET, 393(10168), 253-264. ELSEVIER SCIENCE INC
The Lancet, 393(10168), 253-264. Elsevier Limited

مصطلحات موضوعية: Male, Time Factors, DIAGNOSED MULTIPLE-MYELOMA, Clinical Trial, Phase III, Administration, Oral, 030204 cardiovascular system & hematology, Ixazomib, chemistry.chemical_compound, 0302 clinical medicine, Autologous stem-cell transplantation, Maintenance therapy, Clinical endpoint, 030212 general & internal medicine, Non-U.S. Gov't, Boron Compounds/administration & dosage, IMPROVES SURVIVAL, INDUCTION, Research Support, Non-U.S. Gov't, General Medicine, CHEMOTHERAPY, Middle Aged, Clinical Trial, DEXAMETHASONE, Antineoplastic Agents/administration & dosage, Multicenter Study, Treatment Outcome, Administration, Randomized Controlled Trial, Disease Progression, Female, Multiple Myeloma, Autologous, Boron Compounds, Oral, medicine.medical_specialty, Glycine, Multiple Myeloma/drug therapy, BORTEZOMIB, Antineoplastic Agents, Placebo, Research Support, Transplantation, Autologous, 03 medical and health sciences, Phase III, Double-Blind Method, Internal medicine, medicine, Journal Article, Humans, THALIDOMIDE, Transplantation, business.industry, Clinical trial, LENALIDOMIDE MAINTENANCE, Regimen, chemistry, autologous stem cell transplantation, multiple myeloma, Ixazomib, business, HIGH-DOSE THERAPY, Glycine/administration & dosage, Stem Cell Transplantation